Sinovac Biotech, Long Term Debt

Sinovac Biotech, (SVA) currently reports a long-term debt of $140M as of June 2024. That compares with $52M in the prior-year period — up 174.9% year over year. Use the charts on this page to explore Sinovac Biotech,'s long-term debt history and peer comparisons.

Sinovac Biotech,'s long-term debt increased from $52M to $140M — a 174.9% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sinovac Biotech, reported $140M in long-term debt as of June 2024. That compares with $52M in the prior-year period — up 174.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $140M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.

Sinovac Biotech, is classified in the Healthcare sector. On long-term debt, it currently shows $140M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SVA with unrelated industries.